Azahaf S, Spit K A, de Blok C J M, Nanayakkara P W B
Section General Internal Medicine, Department of Internal Medicine, Amsterdam University Medical Centres, Amsterdam, The Netherlands.
Sci Rep. 2025 Jan 29;15(1):3652. doi: 10.1038/s41598-025-88013-4.
Breast Implant Illness (BII) is characterized by a cluster of systemic and local symptoms affecting a subset of women with silicone breast implants. While symptom improvement is frequently observed following implant removal, the underlying mechanisms remain poorly understood, and the absence of reliable biomarkers complicates clinical decision-making. Here, we investigate inflammatory protein profiles in 43 women with BII, comparing pre- and post-explantation levels using the Olink Target 96 Inflammation panel and Meso Scale Discovery technology for absolute quantification. Sixteen inflammatory proteins, including MCP-1, CD8A, and CCL11, were elevated post-explantation, with FGF-19 showing the most pronounced increase (64%). FGF-19 levels increased from a median of 136 pg/mL to 195 pg/mL (p = 0.001), comparable to levels in women with silicone breast implants but no BII. We propose that explantation may alleviate FGF-19 signaling disruption, restoring its metabolic benefits. These findings suggest FGF-19 as a potential diagnostic and therapeutic marker for BII, warranting further investigation.
乳房植入物疾病（BII）的特征是一系列全身和局部症状，影响了一部分植入硅胶乳房植入物的女性。虽然在移除植入物后症状常常有所改善，但其潜在机制仍知之甚少，且缺乏可靠的生物标志物使临床决策变得复杂。在此，我们研究了43名患有BII的女性的炎症蛋白谱，使用Olink Target 96炎症检测板和Meso Scale Discovery技术进行绝对定量，比较植入物移除前后的水平。包括MCP-1、CD8A和CCL11在内的16种炎症蛋白在移除植入物后升高，其中FGF-19的增加最为显著（64%）。FGF-19水平从中位数136 pg/mL增加到195 pg/mL（p = 0.001），与有硅胶乳房植入物但无BII的女性水平相当。我们认为移除植入物可能减轻FGF-19信号传导中断，恢复其代谢益处。这些发现表明FGF-19作为BII的潜在诊断和治疗标志物，值得进一步研究。
